Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.30
-0.06-4.41%
At close: -
$1.36
0.064.62%
After Hours: 8:04 AM EDT
Comments
Loading...
Citius Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:CTXR | Benzinga
Citius Pharmaceuticals Inc has a consensus price target of $6.33 based on the ratings of 3 analysts. The high is $9 issued by D. Boral Capital on February 18, 2025. The low is $4 issued by HC Wainwright & Co. on November 12, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital on February 18, 2025, January 7, 2025, and December 30, 2024, respectively. With an average price target of $9 between D. Boral Capital, there's an implied 561.76% upside for Citius Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Citius Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/18/2025 | Buy Now | 561.76% | D. Boral Capital | Jason Kolbert48% | $9 → $9 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | 561.76% | D. Boral Capital | Jason Kolbert48% | $9 → $9 | Maintains | Buy | Get Alert |
| 12/30/2024 | Buy Now | 561.76% | D. Boral Capital | Jason Kolbert48% | → $9 | Upgrade | Hold → Buy | Get Alert |
| 11/22/2024 | Buy Now | — | D. Boral Capital | Jason Kolbert48% | — | Downgrade | Buy → Hold | Get Alert |
| 11/12/2024 | Buy Now | 194.12% | HC Wainwright & Co. | Vernon Bernardino51% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 341.18% | D. Boral Capital | Jason Kolbert48% | $150 → $150 | Maintains | Buy | Get Alert |
| 08/19/2024 | Buy Now | 341.18% | EF Hutton | Jason Kolbert48% | $150 → $150 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 341.18% | EF Hutton | Jason Kolbert48% | $150 → $150 | Maintains | Buy | Get Alert |
| 08/05/2024 | Buy Now | 341.18% | EF Hutton | Jason Kolbert48% | $150 → $150 | Maintains | Buy | Get Alert |
| 07/15/2024 | Buy Now | 341.18% | EF Hutton | Jason Kolbert48% | → $150 | Initiates | → Buy | Get Alert |
| 05/31/2024 | Buy Now | 194.12% | HC Wainwright & Co. | Vernon Bernardino51% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 02/14/2024 | Buy Now | 194.12% | HC Wainwright & Co. | Vernon Bernardino51% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 194.12% | HC Wainwright & Co. | Vernon Bernardino51% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 194.12% | HC Wainwright & Co. | Vernon Bernardino51% | $150 → $100 | Maintains | Buy | Get Alert |
| 05/30/2023 | Buy Now | 341.18% | HC Wainwright & Co. | Vernon Bernardino51% | → $150 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | 341.18% | HC Wainwright & Co. | Vernon Bernardino51% | → $150 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 341.18% | HC Wainwright & Co. | Vernon Bernardino51% | → $150 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Citius Pharmaceuticals (CTXR) stock?
The latest price target for Citius Pharmaceuticals (NASDAQ:CTXR) was reported by D. Boral Capital on February 18, 2025. The analyst firm set a price target for $9.00 expecting CTXR to rise to within 12 months (a possible 561.76% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Citius Pharmaceuticals (CTXR)?
The latest analyst rating for Citius Pharmaceuticals (NASDAQ:CTXR) was provided by D. Boral Capital, and Citius Pharmaceuticals maintained their buy rating.
When was the last upgrade for Citius Pharmaceuticals (CTXR)?
The last upgrade for Citius Pharmaceuticals Inc happened on December 30, 2024 when D. Boral Capital raised their price target to $9. D. Boral Capital previously had a hold for Citius Pharmaceuticals Inc.
When was the last downgrade for Citius Pharmaceuticals (CTXR)?
The last downgrade for Citius Pharmaceuticals Inc happened on November 22, 2024 when D. Boral Capital changed their price target from N/A to N/A for Citius Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Citius Pharmaceuticals (CTXR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharmaceuticals was filed on February 18, 2025 so you should expect the next rating to be made available sometime around February 18, 2026.
Is the Analyst Rating Citius Pharmaceuticals (CTXR) correct?
While ratings are subjective and will change, the latest Citius Pharmaceuticals (CTXR) rating was a maintained with a price target of $9.00 to $9.00. The current price Citius Pharmaceuticals (CTXR) is trading at is $1.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.